Nab-Paclitaxel and Durvalumab With or Without Neoantigen Vaccine in Treating Patients With Metastatic Triple Negative Breast Cancer

Conditions:   Anatomic Stage IV Breast Cancer AJCC v8;   Estrogen Receptor Negative;   HER2/Neu Negative;   Metastatic Triple-Negative Breast Carcinoma;   Progesterone Receptor Negative;   Prognostic Stage IV Breast Cancer AJCC v8 Interventions:   Drug: Carboplatin;   Biological: Durvalumab;   Drug: Gemcitabine Hydrochloride;   Drug: Nab-paclitaxel;   Biological: Personalized Synthetic Long Peptide Vaccine;   Drug: Poly ICLC Sponsor:   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials